Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop or slow the growth of cancer cells. Epoetin alfa may
stimulate red blood cell production. Combining thalidomide with epoetin alfa may improve
anemia, decrease the need for blood transfusions, and improve the quality of life in patients
with myelodysplastic syndrome.
PURPOSE: Phase II trial to study the effectiveness of combining thalidomide with epoetin alfa
in treating anemia in patients who have myelodysplastic syndrome.